Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva

Overview

Journal J Pediatr Pharmacol Ther

Specialty Pediatrics

Date 2016 Jan 15

PMID 26766933

Citations 5

Authors

Bjoern B Burckhardt

Jutta Tins

Sergej Ramusovic

Stephanie Laer

Affiliations

Soon will be listed here.

Abstract

Objectives: Drugs that are effectively used to treat hypertension in adults (e.g., enalapril) have not been sufficiently investigated in children. Studies required for pediatric approval require special consideration regarding ethics, study design, and conduct and are also associated with special demands for the bioanalytic method. Pediatric-appropriate assays can overcome these burdens and enable systematic investigations of pharmacokinetics and pharmacodynamic in all pediatric age groups.

Methods: Tailored assays were developed for pharmacokinetic investigation of a drug in 100 μL of serum, saliva, and urine. All assays were applied in a proof-of-concept study to 22 healthy volunteers who had been given 300 mg aliskiren hemifumarate or 20 mg enalapril maleate and allowed for dense sampling. Changes in humoral parameters of the renin-angiotensin-aldosterone system were also evaluated with 6 parameters in 2.1 mL blood per time point.

Results: The pharmacokinetic results of aliskiren and enalapril obtained by low-volume assays in serum and urine were comparable to that noted in the literature. The dense sampling enabled very detailed concentration-time profiles that showed high intersubject variability and biphasic absorption behavior of aliskiren. The replacement of invasive sampling by saliva collection appears inappropriate for both drugs because the correlations of drug concentrations in both fluids were low. A low-volume assay was also used to determine values for in the renin-angiotensin-aldosterone system and to compare those results with the published literature.

Conclusion: These results support both the use of low-volume assays in pediatric research and the systematic investigation of their use in neonates and infants. Use of this assay methodology will increase information about drug pharmacokinetics and pharmacodynamics in this vulnerable population and might contribute to safe and effective use of pharmacotherapy.

Citing Articles

Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer.

Darwish I, Alzoman N, Khalil N, Darwish H Heliyon. 2023; 9(6):e15782.

PMID: 37389074 PMC: 10300215. DOI: 10.1016/j.heliyon.2023.e15782.

Enalapril and Enalaprilat Pharmacokinetics in Children with Heart Failure Due to Dilated Cardiomyopathy and Congestive Heart Failure after Administration of an Orodispersible Enalapril Minitablet (LENA-Studies).

Laeer S, Cawello W, Burckhardt B, Ablonczy L, Bajcetic M, Breur J Pharmaceutics. 2022; 14(6).

PMID: 35745735 PMC: 9228797. DOI: 10.3390/pharmaceutics14061163.

Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets.

Faisal M, Cawello W, Burckhardt B, de Hoon J, Laer S Front Pediatr. 2019; 7:281.

PMID: 31338356 PMC: 6629781. DOI: 10.3389/fped.2019.00281.

Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study.

Bajcetic M, de Wildt S, Dalinghaus M, Breitkreutz J, Klingmann I, Lagler F Contemp Clin Trials Commun. 2019; 15:100393.

PMID: 31249901 PMC: 6586986. DOI: 10.1016/j.conctc.2019.100393.

Adropin as a potential marker of enzyme-positive acute coronary syndrome.

Aydin S, Eren M, Yilmaz M, Kalayci M, Yardim M, Alatas O Cardiovasc J Afr. 2016; 28(1):40-47.

PMID: 27196807 PMC: 5423434. DOI: 10.5830/CVJA-2016-055.

References

Lurbe E, Cifkova R, Cruickshank J, Dillon M, Ferreira I, Invitti C . Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009; 27(9):1719-42. DOI: 10.1097/HJH.0b013e32832f4f6b. View

Gonzalez O, Iriarte G, Rico E, Ferreiros N, Maguregui M, Alonso R . LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(28):2685-92. DOI: 10.1016/j.jchromb.2010.07.026. View

Ghosh C, Jain I, Shinde C, Chakraborty B . Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. Drug Test Anal. 2011; 4(2):94-103. DOI: 10.1002/dta.241. View

Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M . Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007; 35(8):1418-28. DOI: 10.1124/dmd.106.013797. View

Glover V, Miles R, Matta S, Modi N, Stevenson J . Glucocorticoid exposure in preterm babies predicts saliva cortisol response to immunization at 4 months. Pediatr Res. 2005; 58(6):1233-7. DOI: 10.1203/01.pdr.0000185132.38209.73. View

Ulm E, HICHENS M, Gomez H, Till A, Hand E, Vassil T . Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982; 14(3):357-62. PMC: 1427630. DOI: 10.1111/j.1365-2125.1982.tb01991.x. View

Wells T, Rippley R, Hogg R, Sakarcan A, Blowey D, Walson P . The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol. 2001; 41(10):1064-74. DOI: 10.1177/00912700122012661. View

Gu Q, Chen X, Zhong D, Wang Y . Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 813(1-2):337-42. DOI: 10.1016/j.jchromb.2004.09.031. View

Burckhardt B, Ramusovic S, Tins J, Laeer S . Determination of aliskiren in human serum quantities by HPLC-tandem mass spectrometry appropriate for pediatric trials. Biomed Chromatogr. 2012; 27(4):477-86. DOI: 10.1002/bmc.2815. View

10.

Nussberger J, Gradman A, Schmieder R, Lins R, Chiang Y, Prescott M . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007; 61(9):1461-8. DOI: 10.1111/j.1742-1241.2007.01473.x. View

11.

Kelly J, Doyle G, Donohue J, Laher M, Vandenburg M, Currie W . Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. Br J Clin Pharmacol. 1986; 21(1):63-9. PMC: 1400811. DOI: 10.1111/j.1365-2125.1986.tb02823.x. View

12.

Lloyd T, Mahoney L, Knoedel D, Marvin Jr W, Robillard J, Lauer R . Orally administered enalapril for infants with congestive heart failure: a dose-finding study. J Pediatr. 1989; 114(4 Pt 1):650-4. DOI: 10.1016/s0022-3476(89)80715-2. View

13.

Nakamura H, Ishii M, Sugimura T, Chiba K, Kato H, Ishizaki T . The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Clin Pharmacol Ther. 1994; 56(2):160-8. DOI: 10.1038/clpt.1994.119. View

14.

Ramusovic S, Thielking G, Laer S . Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. Biomed Chromatogr. 2011; 26(6):697-702. DOI: 10.1002/bmc.1716. View

15.

Till A, Gomez H, HICHENS M, Bolognese J, McNabb W, Brooks B . Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos. 1984; 5(3):273-80. DOI: 10.1002/bdd.2510050309. View

16.

Lass J, Kaar R, Jogi K, Varendi H, Metsvaht T, Lutsar I . Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. Eur J Clin Pharmacol. 2011; 67(12):1263-71. DOI: 10.1007/s00228-011-1072-x. View

17.

Hiremath G, Olive A, Shah S, Davis C, Shulman R, Devaraj S . Comparing methods to collect saliva from children to analyze cytokines related to allergic inflammation. Ann Allergy Asthma Immunol. 2014; 114(1):63-4. PMC: 4307382. DOI: 10.1016/j.anai.2014.09.012. View

18.

Lee J, Son J, Lee M, Lee K, Kim D . Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96-well solid-phase extraction and liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003; 17(11):1157-62. DOI: 10.1002/rcm.1040. View

19.

Vaidyanathan S, Jarugula V, Dieterich H, Howard D, Dole W . Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008; 47(8):515-31. DOI: 10.2165/00003088-200847080-00002. View

20.

Noormohamed F, McNabb W, Lant A . Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. J Pharmacol Exp Ther. 1990; 253(1):362-8. View